【摘要】：目的：了解新輔助化療反應性對宮頸癌患者遠期預后的影響。方法：電子檢索PubMed、MEDLINE、Web of Knowledge、Google、中國知網(wǎng)數(shù)據(jù)庫、維普科技期刊數(shù)據(jù)庫搜索文獻，根據(jù)異質(zhì)性檢測決定使用固定或隨機效應模型進行效應量比值比（OR）合并統(tǒng)計，用RevMan.5.2統(tǒng)計學軟件進行統(tǒng)計處理。結果：共有14篇文章共1326名患者納入，化療有效反應率波動在39.8%-97.3%（實體瘤評價標準評價）及27.6%、28.6%（手術標本病理診斷評價），2-year PFS/OS效應量比值比OR分別為4.67（95%CI3.35-6.77；Z=8.68P=0.00）、4.39（95%CI2.53-7.61；Z=5.26P=0.00），，5-year PFS/OS效應量比值比OR分別為5.36（95%CI3.59-7.99；Z=8.23P=0.00）、5.80（95%CI3.83-8.79；Z=8.30P=0.00）。X2檢驗及I2檢驗提示各納入研究無顯著異質(zhì)性，漏斗圖提示無顯著發(fā)表偏倚，通過改變效應統(tǒng)計模型、去除大樣本進行敏感性分析，提示該meta分析結果穩(wěn)定。結論：宮頸癌術前新輔助化療有效的化療反應性可改善遠期預后。
[Abstract]:Objective: to investigate the effect of neoadjuvant chemotherapeutic reactivity on long-term prognosis in patients with cervical cancer. Methods: PubMed,MEDLINE,Web of Knowledge,Google, China knowledge Network Database and Wiper Science and Technology Journal Database were searched electronically. According to the heterogeneity test, fixed or random effect models were used to combine the ratio of effect volume to (OR). RevMan.5.2 statistical software was used to deal with the statistics. Results: a total of 1326 patients were included in 14 articles. The effective response rate of chemotherapy varied from 39.8% to 97.3% (evaluation criteria for solid tumors) and 27.62.6% (pathological diagnosis of surgical specimens). The ratio of 2-year PFS/OS effect to OR was 4.67 (95CI3.35-6.77Z8.68P0.00) and 4.39 (95CI2.53-7.61), respectively. Z=5.26P=0.00), the ratio of 5-year PFS/OS effect volume to OR was 5.36 (95CI3.59-7.99) and 5.80 (95CI3.83-8.79ZH 8.30P0.00) respectively. X2 test and I2 test showed that there was no significant heterogeneity in each study, and funnel diagram showed no significant bias. The sensitivity analysis was carried out by changing the statistical model of effect and removing large samples. These results suggest that the meta analysis results are stable. Conclusion: preoperative neoadjuvant chemotherapy can improve the long-term prognosis of cervical cancer.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R737.33

【參考文獻】

相關期刊論文 前7條

1 張建;胡興;孫亞軍;狄鎮(zhèn)海;鄒容;任重陽;毛學群;王美榮;張愛琴;;子宮動脈化療栓塞治療宮頸癌33例臨床分析[J];介入放射學雜志;2011年04期

2 毛家仁;貢琪;呂益忠;;宮頸癌(Ⅰb～Ⅲb期)介入治療療效的影響因素分析[J];臨床放射學雜志;2012年02期

3 曾憲濤;劉慧;陳曦;冷衛(wèi)東;;Meta分析系列之四:觀察性研究的質(zhì)量評價工具[J];中國循證心血管醫(yī)學雜志;2012年04期

4 楊學寧,吳一龍;實體瘤治療療效評價標準——RECIST[J];循證醫(yī)學;2004年02期

5 張偉;賀毅憬;周宏灝;;遺傳藥理學的學科發(fā)展與未來[J];中國臨床藥理學與治療學;2008年09期

6 ;超選擇子宮動脈灌注新輔助化療在局部晚期宮頸癌治療中的作用(英文)[J];Chinese-German Journal of Clinical Oncology;2009年09期

7 高國蘭;萬紅英;鄒學森;陳文學;陳岳青;黃秀珍;;子宮頸癌組織三磷酸腺苷腫瘤體外藥物敏感試驗及其與耐藥蛋白表達的關系[J];中華婦產(chǎn)科雜志;2007年03期

本文編號：2274153